Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | A.R.R.O.W. study: carfilzomib dosing in frail MM patients

Maria-Victoria Mateos, MD, PhD from the University of Salamanca, Salamanca, Spain, gives an update on the Phase III A.R.R.O.W. study (NCT02412878) looking at carfilzomib dosing in frail MM patients. Dr Mateos was speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.